InfoCons Consumer Protection informs you – Ziagen – Package Leaflet

Ziagen – Package Leaflet: InfoCons – Consumer Protection presents, in an accessible format, the official package leaflet of the medicine Ziagen, as authorised in the European Union and published in the Union Register of medicinal products.

📋 Ziagen – at a glance
Active substance abacavir sulfate
ATC code J05AF06
EU authorisation number EU/1/99/112
Marketing Authorisation Holder ViiV Healthcare BV
Therapeutic indication Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children. The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in…
Last Commission decision 2024-09-06

Before anything else

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you .

  • Keep this leaflet. Y ou may need to read it again.
  • If you have any further questions ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

IMPORTANT – Hypersensitivity reactions Ziagen contains abacavir (which is also an active subs tance in medicines such as Kivexa , Triumeq and Trizivir ). Some people who take abacavir may develop a hypersensitivity reaction (a serious allergic reaction), which can be life- threatening if they continue to take abacavir containing products .

You must carefully read all the information under ‘Hypersensitivity reactions’ in the panel in Section 4 .

The Ziagen pack includes an Alert Card , to remind you and medical staff about abacavir hypersensitivity. Detach this card and keep it with you at all time s.

ℹ️ 1. What Ziagen is and what it is used for

Ziagen is used to treat HIV (human immunodeficiency virus) infection.

Ziagen contains the active ingredient abacavir. Abacavir belongs to a group of anti -retroviral medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs) .

Ziagen does not completely cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cell that are important in helping your body to fight infection.

Not everyone responds to treatment with Ziagen in the same way. Your doctor will monitor the effectiveness of your treatment.

⚠️ 2. What you need to know before you take Ziagen

62 Do not take Ziagen:

  • if you a re allergic (hypersensitive) to abacavir (or any other medicine containing abacavir – such as Triumeq, Trizivir or Kivexa) or any of the other ingredients of this medicine (listed in Section 6) Carefully read all the information about hypersensitivity reactions in Section 4 .

Check with your doctor if you think this applies to you.

Take special care with Ziagen Some people taking Ziagen for HIV are more at risk of serious side effects. You need to be aware of the extra risks:

  • if you have moderate or severe liver disease
  • if you have eve r had liver disease, including hepatitis B or C
  • if you are seriously overweight (especially if you a re a woman)
  • if you have severe kidney disease Talk to your doctor if any of these apply to you . You may need extra check -ups, including blood tests, while you are taking your medicine. See Section 4 for more information .

Abacavir hypersensitivity reactions Even patients who don’t have the HLA -B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction).

Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.

Risk of cardiovascular events It cannot be excluded that abacavir may increase the risk of having cardiovascular events.

Tell your doctor if you have cardiovascular problems, if you smoke, or have other illnesses that may increase your risk of cardiovascular disease s such as high blood pressure, or diabetes. Do not stop taking Ziagen unless your doctor advises you to do so.

Look out for important symptoms Some people taking medicines for HIV infection develop other conditions, which can be serious. You need to know about impo rtant signs and symptoms to look out for while you are taking Ziagen.

Read the information ‘Other possible side effects of combination therapy for HIV’ in Section 4 of this leaflet .

Other medicines and Ziagen

Tell your doctor or pharmacist if you are taking any other medicines , or if you have taken any recently, including herbal medicines or other medicines you bought without a presc ription. Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Ziagen.

Some medicines interact with Ziagen These include:

  • phenytoin, for treating epilepsy .

Tell your doctor if you are taking phenytoin. Your doctor may need to monitor you while you are taking Ziagen.

  • methadone used as a heroin substitute. Abacavir increases the rate at which methadone is removed from the body. If you are taking methadone, you will be checked for any withdrawal symptoms. Your methadone dose may need to be changed.

Tell your doctor if you are taking methadone.

  • Riociguat, for treating high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. Your doctor may need to reduce your riociguat dose, as abacavir may increase riociguat blood levels.

63 Pregnancy Ziagen is not recommended for use during pregnancy . Ziagen and similar medicines may cause side effects in unborn babies. If you have taken Ziagen during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monit or the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

Breast -feeding Breast -feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. A small amount of the ingredients in Ziagen can also pass into your breast milk.

If you are breast -feeding, or thinking about breast -feeding , you should discuss it with your doctor as soon as possible .

Driving and using machines

Do not drive or operate machines unless you are feeling well.

Important information about some of the other ingredients of Ziagen oral solution This medicine contains the sweetener sorbitol (approximately 5g in each 15 ml dose), which may have a mil d laxative effect. Do not take medicines containing sorbitol if you have hereditary fructose intolerance. The calorific value of sorbitol is 2.6 kcal/g.

Ziagen also contains preservatives (parahydroxybenzoates) which may cause allergic reactions (possibly delayed).

This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium -free’.

Ziagen oral solution contains 50 mg/ml of propylene glycol . When taken according to the dosage recommendations each 15 ml dose contains approximately 750 mg of propylene glycol .

  • If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol.
  • If you are pregnant or breast -feeding, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.
  • If you suffer from a liver or kidney disease, do not take this medicine unless recommended by y our doctor. Your doctor may carry out extra checks while you are taking this medicine.

💊 3. How to take Ziagen

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Ziagen can be taken with or without food.

Stay in regular contact with your doctor Ziagen helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to H IV infection.

Keep in touch with your doctor, and do not stop taking Ziagen without your doctor’s advice.

How much to take Adults , adolescents and children weighing at least 25 kg The usual dose of Ziagen is 600 mg (30 m l) a day. This can be taken either as 300 mg (15 ml) twice a day or 600 mg (30 ml) once a day.

Children from 3 months of age weighing less than 25 kg The dose depends on the child’s body weight. The recommended dose is 8 mg/kg twice a day or 16 mg/kg once a day, up to a maximum total daily dose of 600 mg daily.

How to measure the dose and take the medicine Use the oral dosing syringe supplie d with the pack to measure your dose accurately. When full, the syringe contains 10 m l of solution.

1. Remove the plastic wrap from the syringe/adapter 2. Remove the bottle cap. Keep it safely.

3. Remove the adapter from the syringe.

4. Hold the bottle firmly. Push the plastic adapter into the neck of the bottle 5. Insert the syringe firmly into the adapter 6. Turn bottle upside down 7. Pull out the syringe plunger until the syringe contains the first part of your full dose 8. Turn the bottle the ri ght way up. Remove the syringe from the adapter 9. Put the syringe into your mouth, placing the tip of the syringe against the inside of your cheek.

Slowly push the plunger in, allowing time to swallow. Don’t push too hard and squirt the liquid into the back of your throat, or you may choke 10. Thoroughly clean the syringe each time it has been emptied 11. Repeat steps 5 to 10 in the same way until you have taken your whole dose. For example, if your dose is 30 ml, y ou need to take 3 syringe -fulls of medicine 12. After you have taken your complete dose , wash the syringe thoroughly in clean water. Let it dry completely before you use it again 13. Close the bottle tightly with the cap, leaving the adapter in place

If you take more Ziagen than you should

If you accidentally take too much Ziagen, tell your doctor or your pharmacist, or contact your nearest hospital emergency department for further advi ce.

If you forget to take Ziagen

If you forget to take a dose, take it as soon as you remember. Then continue your treatment as before.

Do not take a double dose to make up for a forgotten dose.

It is important to take Ziagen regularly, because if you take it at irregular intervals, you may be more likely to have a hypersensitivity reaction.

If you have stopped taking Ziagen If you have stopped taking Ziagen for any reason – especially because you think you are having side effects, or because you have other illness:

Talk to your doctor before you st art taking it again . Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been related, you will be told never again to take Ziagen, or any other medicine containing abacavir (e.g.Triu meq, Trizivir or Kivexa) . It is important that you follow this advice.

If your doctor advises that you can start taking Ziagen again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.

❗ 4. Possible side effects

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life styl e, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

Like all medicines, this medicine can cause side effects, although not everyone gets them.

When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Ziagen or other medicines you are taking, or an effect of the HIV disease itse lf. So it is very important to talk to your doctor about any changes in your health .

Even patients who don’t have the HLA -B*5701 gene may still develop a hypersensitivity reaction (a serious allergic reaction), described in this leaflet in the panel headed ‘ Hypersensitivity reactions’.

It is very important that you read and understand the information about this serious reaction .

As well as the side effects listed below for Ziagen , other conditions can develop during combination therapy for HIV.

It is important to read the information later in this section under ‘Other possible side effects of combination therapy for HIV’.

Hypersensitivity reactions Ziagen contains abacavir (which is also an active substance in Kivexa , Triumeq and Trizivir ).

Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction.

These hypersensitivity reactions have been seen more frequently in people taking medicines that contain abacavir.

Who gets these reactions?

Anyone taking Ziagen could develop a hypersensitivity reaction to abacavir, which could be life threatening if they continue to take Ziagen.

You are more likely to develop such a reaction if you have the HLA -B*5701 gene (but you can get a reaction even if you do not have this gene). You should have been tested for this gene before Ziagen was prescribed for you. If you know you have this gene, tell your doctor before you take Ziag en.

About 3 to 4 in every 100 patients treated with abacavir in a clinical trial who did not have the HLA- B*5701 gene develop ed a hypersensitivity reaction.

What are the symptoms?

The most common symptoms are:

  • fever (high temperature) and skin rash Other common symptoms are:
  • nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness Other symptoms include:

Pains in the joints or muscles, swelling of the neck, shortness of breath, sore throat, cough, occasional headaches, inflammation of the eye (conjunctivitis), mouth ulcers, low blood pressure, tingling or numbness of the hands or feet.

When do these reactions happen?

66 Hypersensitivity reactions can start at any time during treatment with Ziagen, but are more likely during the first 6 weeks of treatment.

If you are caring for a child who is b eing treated with Ziagen, it is important that you understand the information about this hypersensitivity reaction. If your child gets the symptoms described below it is essential that you follow the instructions given.

Contact your doctor immediately:

1 if you get a skin rash, OR 2 if you get symptoms from at least 2 of the following groups:

  • fever
  • shortness of breath, sore throat or cough
  • nausea or vomiting, diarrhoea or abdominal pain
  • severe tiredness or achiness, or generally feeling ill Your doctor may advise you to stop taking Ziagen .

If you have stopped taking Ziagen If you have stopped taking Ziagen because of a hypersensitivity reaction, you must NEVER AGAIN take Ziagen, or any other medicine containing abacavir (e.g. Trizivir , Triumeq or Kivexa) . If you do, within hours, your blood pressure could fall dangerously low, which could result in death.

If you have stopped taking Ziagen for any reason – espe cially because you think you are having side effects, or because you have other illness:

Talk to your doctor before you start again . Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been, you will then be told never again to take Ziagen, or any other medicine containing abacavir (e.g. Trizivir , Triumeq or Kivexa) . It is important that you follow this advice.

Occasionally, hypersensitivity reactions have developed in people who star t taking abacavir containing products again, but who had only one symptom on the Alert Card before they stopped taking it.

Very rarely, patients who have taken medicines containing abacavir in the past without any symptoms of hypersensitivity have develop ed a hypersensitivity reaction when they start taking these medicines again.

If your doctor advises that you can start taking Ziagen again, you may be asked to take your first doses in a place w here you will have ready access to medical care if you need it.

If you are hypersensitive to Ziagen, return all your unused Ziagen oral solution for safe disposal.

Ask your doctor or pharmacist for advice.

The Ziagen pack includes an Alert Card , to rem ind you and medical staff about hypersensitivity reactions . Detach this card and keep it with you at all times .

Common side effects

These may affect up to 1 in 10 people:

  • hypersensitivity reaction
  • feeling sick (nausea)
  • headache
  • being sick (vomiting)
  • diarrhoea
  • loss of appetite
  • tiredness, lack of energy
  • fever (high temperature)
  • skin rash

Rare side effects

These may affect up to 1 in 1,000 people:

  • inflammation of the pancreas (pancreatitis)

Very rare side effects

These may affect up to 1 in 10,000 people:

  • skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
  • a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens–Johnson syndrome) , and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis) .
  • lactic acidosis (excess lactic acid in the blood) If you notice any of these symptoms contact a doctor urgently .

If you get side effects Tell your doctor or pharmacist if any of the side effects gets severe or tr oublesome, or if you notice any side effects not listed in this leaflet.

Other possible side effects of combination therapy for HIV Combination therapy including Ziagen may caus e other conditions to develop during HIV treatment.

Symptoms of infection and inflammation Old infe ctions may flare up People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body’s immune system becoming stronger, so that the body starts to fight these infections. Symptoms usually include fever , plus some of the following:

  • headache
  • stomach ache
  • difficulty breathing In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders ). The symptoms of autoimmune disorders may develop many months after you start taking medicine to treat your HIV infection. S ymptoms may include:
  • palpitations (rapid or irregular heartbeat) or tremor
  • hyperactivity (excessive restlessness and movement)
  • weakn ess beginning in the hands and feet and moving up towards the trunk of the body If you get any symptoms of infection while you are taking Ziagen:

Tell your doctor immediately . Do not take other medicines for the infection without your doctor’s advice.

You may have problems with your bones Some people taking combination therapy for HIV develop a condition called osteonecrosis. With this condition, parts of the bone tis sue die because of reduced blood supply to the bone. People may be more likely to get this condition:

  • if they have been taking combination therapy for a long time
  • if they are also taking anti -inflammatory medicines called corticosteroids
  • if they drink alcohol 68 • if their immune systems are very weak
  • if they are overweight Signs of osteonecrosis include:
  • stiffness in the joints
  • aches and pains (especially in the hip, knee or shoulder)
  • difficulty moving If you notice any of these symptoms:

Tell your doctor .

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V . By reporting side effects you can help provide more information on the safety of this medicine.

🌡️ 5. How to store Ziagen

Keep this medicine out of the sight and reach of children.

Do not take this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

Do not store above 25 °C.

Discard oral solution two months after first opening.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures protect the environment.

📦 6. Contents of the pack and other information

What Ziagen contains

The active substance in Ziagen oral solution is 20 mg of abacavir (as sulfate ) in each ml of the solution.

The other ingredients are sorbitol 70% (E420), saccharin sodium, sodium citrate, citric acid anhydrous, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), propylene glycol (E1520), maltodextrin, lactic aci d, glyceryl triacetate, artificial strawberry and banana flavour, purified water , sodium hydroxide and/or hydrochloric acid for pH adjustment.

What Ziagen looks like and contents of the pack

Ziagen oral solution is clear to yellowish in colour which may turn into a brown colour over time with strawberry/banana flavouring. It is supplied in cartons containing a white polyethylene bottle, with a child resistant cap. The bottle contains 240 ml (20 mg abacavir/ ml) of solution. A 10 m l oral dosing syringe and a plastic adapter for the bottle are included in the pack.

Marketing Authorisation Holder: ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort , Netherlands Manufacturer: ViiV Healthcare Trading Services UK Limit ed, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland For any information about this medicine , please contact the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel: + 32 (0) 10 85 65 00 Lietuva ViiV Healthcare BV Tel: + 370 80000334 България ViiV Healthcare BV Teл.: + 359 80018205 Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel: + 32 (0) 10 85 65 00 Česká republika GlaxoSmithKline s.r.o.

Tel: + 420 222 001 111 [email protected] Magyarország ViiV Healthcare BV Tel.: + 36 80088309 Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 [email protected] Malta ViiV Healthcare BV Tel: + 356 80065004 Deutschland ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038- 10 [email protected] Nederland ViiV Healthcare BV Tel: + 31 (0) 33 2081199 Eesti ViiV Healthcare BV Tel: + 372 8002640 Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 [email protected] Ελλάδα GlaxoSmithKline Μονοπρόσωπη A.E.B.E.

Τηλ: + 30 210 68 82 100 Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 [email protected] España Laboratorios ViiV Healthcare, S.L.

Tel: +34 900 923 501 [email protected] Polska GSK Services Sp. z o.o.

Tel.: + 48 (0)22 576 9000 France ViiV Healthcare SAS Tél.: + 33 (0)1 39 17 6969 [email protected] Hrvatska ViiV Healthcare BV Tel: + 385 800787089 Portugal VIIV HIV HEALTHCARE, UNIPESSOAL, LDA Tel: + 351 21 094 08 01 [email protected] România ViiV Healthcare BV Tel: + 40 800672524 Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 Slovenija ViiV Healthcare BV Tel: + 386 80688869 70 Ísland Vistor hf.

Sími: +354 535 7000 Slovenská republika ViiV Healthcare BV Tel: + 421 800500589 Italia ViiV Healthcare S.r.l Tel: + 39 (0)45 7741600 Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Κύπρος ViiV Healthcare BV Τηλ: + 357 80070017 Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 [email protected] Latvija ViiV Healthcare BV Tel: + 371 80205045 United Kingdom (Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 [email protected]

This leaflet was last revised in {MM/YYYY}

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu

📄 Package Leaflet – official source

This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Ziagen (PDF, ec.europa.eu).

You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/99/112).

⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.

Other blog posts

keyboard_arrow_up